Skip to main content
Premium Trial:

Request an Annual Quote

Dmitry Samarsky, Steven Tregay

Premium
RXi, the RNAi subsidiary of CytRx, has named Dmitry Samarsky as its vice president of technology development.
 
Samarsky was most recently director of technology development at Dharmacon, a unit of Thermo Fisher Scientific. Prior to that, he was business development manager at Invitrogen.
 
Earlier in his career, Samarsky held various business development roles at Sequitur, an RNAi reagent company acquired by Invitrogen and founded by RXi’s president and CEO, Tod Woolf.
 
Samarsky holds a PhD in biochemistry and molecular biology from the University of Massachusetts, Amherst.
 

 
Adenosine Therapeutics has appointed Steven Tregay to its board of directors.
Tregay is a managing director of the Novartis Option Fund and was recently named a director of Cequent Pharmaceuticals.

The Scan

Tens of Millions Saved

The Associated Press writes that vaccines against COVID-19 saved an estimated 20 million lives in their first year.

Supersized Bacterium

NPR reports that researchers have found and characterized a bacterium that is visible to the naked eye.

Also Subvariants

Moderna says its bivalent SARS-CoV-2 vaccine leads to a strong immune response against Omicron subvariants, the Wall Street Journal reports.

Science Papers Present Gene-Edited Mouse Models of Liver Cancer, Hürthle Cell Carcinoma Analysis

In Science this week: a collection of mouse models of primary liver cancer, and more.